Interview part two: Chang Yi Wang, Chairperson & CEO, UBI Asia, and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
UBI is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.
The company’s product pipeline is filled with a new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on UBI’s proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. The company’s platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire.
UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by the company’s subsidiary UBI-Asia and various sponsorships in product development.
Rm. E, 52F., No.7-5,
Sec. 5, Xinyi Rd.,
Xinyi Dist.,
Taipei City
11049,
Taiwan (R.O.C.)
Tel:886-2-8101-0101
Fax:886-2-8101-0100
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
Kao Su-Chin Chang, founder and chairman of Weidar Chemical and Pharmaceutical, describes the robust development and international expansion of this historical domestic pharmaceutical manufacturer and the company’s enduring commitment to…
Lawrence Gan, President and CEO of Taiwan’s Development Center for Biotechnology (DCB) explains his vision and strategy to enhance DCB’s R&D expertise by adopting some of the best practices of…
Thomas Yuan, the CEO of TFBS Bioscience, documents the tailored added-value that this fast-growing product testing company strives to bring to emerging pharmaceutical and biotech companies in the Asia Pacific…
Grace Yeh, Founder, President, and CEO of PharmaEngine, one of the most eye-catching success stories to recently emerge from Taiwan’s maturing biopharmaceutical sector, documents the main success factors that have…
Du-Shieng Chien, President & CEO of TaiRx, a Taiwan-based biopharmaceutical company focused on unmet medical needs, provides insights into the recent development of CVM 1118, a revolutionary cancer treatment targeting…
Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce tariffs and commercial barriers between the two countries. Obviously, such a deal…
In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with…
In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on the Gre Tai Securities Market (GTSM), built with small to…
The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites…
The Chairman and CSO of TCM Biotech offer perspectives on the potential of botanical drugs, and chart their biotech company’s trajectory in bringing these drugs to both the Chinese and…
The president of Adimmune Corporation discusses how the avian flu outbreak of 2006/2007 changed the course of the drug manufacturing industry in Taiwan, what that meant for Adimmune, and how…
The minister in charge of medical tourism in Taiwan speaks about the country’s advantages over its Asian neighbours, and how the new era of Taiwan’s medical services will…
See our Cookie Privacy Policy Here